Advertisement

International Cancer Conference Journal

, Volume 8, Issue 1, pp 17–23 | Cite as

Double primary recurrent human epidermal growth factor receptor 2-positive breast cancer and esophageal cancer that responded well to chemotherapy

  • Shigehiro Yokoi
  • Hiroyuki Maeda
  • Takuma Nishino
  • Tamotsu Togawa
  • Atsushi Iida
  • Takanori Goi
Case report
  • 6 Downloads

Abstract

Double primary breast and esophageal cancer have been no reported cases in which treatment methods other than surgery were selected because of multiple metastasis or advanced cancer. The patient was a 52-year-old woman who had received left pectoral muscle-preserving mastectomy and axillary lymph node dissection (level 2) 7 years prior, following the diagnosis of left breast cancer. The postoperative diagnosis was pT2 N3a M0 stage IIIC and luminal human epidermal growth factor receptor 2 (HER2) phenotype. After the surgery, six courses of triple chemotherapy with 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide and four courses of docetaxel (DTX) were administered, and letrozole was administered for 5 years. Seven years after the surgery, swelling of her left axillary, supra-, and subclavicular lymph nodes, and sternum osteolysis were observed on computed tomography (CT). Radioisotope uptake was observed in the esophagus on positron emission tomography. An esophageal cancer was observed in the upper thoracic esophagus on esophagogastroscopy. The patient was administered a local treatment for esophageal cancer and systemic chemotherapy for both cancers. As a primary therapy, double chemotherapy with 5-FU and cisplatin (FP) (two courses) + radiotherapy on the esophagus and left supraclavicular lymph nodes (total target dose of radiotherapy was 60 Gy /30 fractions) was performed with the concomitant use of trastuzumab and zoledronate. Marked shrinkage [complete response (CR)] of the esophageal cancer was observed on esophagogastroscopy and shrinkage (partial response) of the left axillary and supra- and subclavicular lymph nodes were observed on CT. The secondary treatment included pertuzumab + trastuzumab + DTX. Bilateral pleural effusions were observed in the eighth course; therefore, DTX was withdrawn and the treatment was continued with only the molecularly targeted drugs. Two years have passed since the initiation of treatment. The individual lymph node metastatic foci have disappeared or markedly shrunk (CR) on CT scans and the sternal metastases have remained hard without change. In addition, CR for esophageal cancer has been maintained. We report a case of double primary recurrent HER2-positive breast cancer and esophageal cancer that responded well to radiotherapy and chemotherapy.

Keywords

HER2-positive breast cancer Esophageal cancer Double primary cancer Chemoradiation therapy (CRT) Triple chemotherapy with pertuzumab, trastuzumab, and docetaxel 

References

  1. 1.
    Sowa M, Kato Y, Kito H et al (1982) Double primary cancer involving breast cancer. J Jpn Surg Assoc 43:651–659Google Scholar
  2. 2.
    Tanaka M, Nishimura Y, Tanaka Y et al (1989) Multiple primary malignant tumor of the breast associated with other organs. J Jpn Surg Assoc 50:298–302Google Scholar
  3. 3.
    Matono S, Sueyoshi S, Tanaka T et al (2004) Clinical analysis of esophageal cancer associated with other primary malignancies. Jpn J Gastroenterol Surg 37:633–639CrossRefGoogle Scholar
  4. 4.
    Akiyama Y, Iwaya T, Shioi Y et al (2015) Successfully treated advanced esophageal cancer with left axillary lymph node metastasis and synchronous right breast cancer: a case report. Surg Case Rep 1:94CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Singh A, Khare IC, Dixit AK et al (2010) Successfully treated synchronous double malignancy of the breast and esophagus: a case report. J Med Case Rep 4:169CrossRefPubMedCentralGoogle Scholar
  6. 6.
    The Japanese Breast Cancer Society (2005) General rules for clinical and pathological recording of breast cancer 2005, 15th edition. Breast Cancer. 12(Suppl.):S1–S27CrossRefGoogle Scholar
  7. 7.
    The Japan Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 14:1–36CrossRefGoogle Scholar
  8. 8.
    Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:637–642Google Scholar
  9. 9.
    Boccardo F, Merlano M, Canobbio L et al (1982) Esophageal involvement in breast cancer. Report of six cases. Tumori 68:149–153CrossRefGoogle Scholar
  10. 10.
    Komatsu S, Ueda Y, Ichikawa D et al (2007) Prognostic and clinical evaluation of axillary lymph node metastasis in esophageal cancer. Jpn J Clin Oncol 37:314–318CrossRefGoogle Scholar
  11. 11.
    Yoshino K, Asanuma F, Hanatani Y et al (1984) Multiple primary cancer of the stomach and other organs. Jpn J Cancer Clin 30:1514–1523Google Scholar
  12. 12.
    Nagase D, Izumi H, Ishihara S et al (2014) A case of synchronous double primary cancer of acute myeloid leukemia and esophageal cancer. Jpn J Clin Exp Med 91:1085–1088Google Scholar
  13. 13.
    The Japan Esophageal Society (2012) Guidelines for diagnosis and treatment of carcinoma of the esophagus, 3rd edn. Kanehara & Co., Ltd, TokyoGoogle Scholar
  14. 14.
    Iizuka T, Hirano N, Kikuchi D et al (2009) A case of simultaneous double primary cancers with multiple liver metastases responding to S-1 + CPT-11. Gan To Kagaku Ryoho 36:139–141Google Scholar
  15. 15.
    Kato K, Muro K, Minashi K et al (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690CrossRefGoogle Scholar
  16. 16.
    Japanese Breast Cancer Society (2015) Clinical Practice guideline for systemic treatment of breast cancer, edition. Kanehara & Co., Ltd, TokyoGoogle Scholar
  17. 17.
    Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Takahashi R, Fujii T, Inoue Y et al (2012) Liver arterial infusion chemotherapy with adjuvant trastuzumab for the simultaneous treatment of liver and breast cancer-a case report. Gan To Kagaku Ryoho 39:1707–1710Google Scholar
  19. 19.
    Pergolizzi S, Adamo V, Russi E et al (2006) Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer woman with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys 65:25–32CrossRefGoogle Scholar
  20. 20.
    Mimura K, Kono K, Hanawa M et al (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11:4898–4904CrossRefGoogle Scholar
  21. 21.
    Mimura K, Izawa S, Siba S et al (2011) The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma. Gan To Kagaku Ryoho 38:1918–1920Google Scholar

Copyright information

© The Japan Society of Clinical Oncology 2018

Authors and Affiliations

  1. 1.First Department of Surgery, School of Medicine, Faculty of Medical SciencesUniversity of FukuiEiheiji-choJapan
  2. 2.SurgeryTsuruga Medical CenterTsurugaJapan

Personalised recommendations